(Q34070142)

30 July 2017

1 reference

title

Replication-competent herpes simplex viral vectors for cancer therapy (English)

1 reference

30 July 2017

2

Roizman B

1 reference

30 July 2017

Markovitz NS

1

1 reference

30 July 2017

publication date

1 January 2000

1 reference

Advances in Virus Research

30 July 2017

published in

1 reference

30 July 2017

volume

55

1 reference

30 July 2017

page(s)

409-424

1 reference

Herpes simplex virus type 2 in the United States, 1976 to 1994.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

The DNA sequences of the long repeat region and adjoining parts of the long unique region in the genome of herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Genetic engineering of novel genomes of large DNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Genetic manipulation of herpes simplex virus using bacterial artificial chromosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

A variant of herpes simplex virus type 2 strain HG52 with a 1.5 kb deletion in RL between 0 to 0.02 and 0.81 to 0.83 map units is non-neurovirulent for mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Targeting gene therapy vectors to CNS malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Act locally, think globally

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Expanded spectrum of viral therapy in the treatment of nervous system tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Therapeutic replication-competent herpes virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Drug inducible transgene expression in brain using a herpes simplex virus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

A novel tetracycline-inducible viral replication switch

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector--potential glioblastoma targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Herpes simplex virus 1 mutant deleted in the alpha 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2800%2955010-6

7 January 2021

10.1016/S0065-3527(00)55010-6

Identifiers

DOI

1 reference

30 July 2017

1 reference